Regulatory Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation Pharmaceutical Business ReviewAuvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication.NeuroscienceRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Business Review Auvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication. Neuroscience Read full story Post navigation Previous: LEO Pharma to acquire gene therapy company ReplayNext: FDA’s ODAC delivers one loss, one win for AstraZeneca Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026